206 related articles for article (PubMed ID: 34037478)
41. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
42. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.
Flowers SA; Colón B; Whaley SG; Schuler MA; Rogers PD
Antimicrob Agents Chemother; 2015 Jan; 59(1):450-60. PubMed ID: 25385095
[TBL] [Abstract][Full Text] [Related]
43. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.
Flowers SA; Barker KS; Berkow EL; Toner G; Chadwick SG; Gygax SE; Morschhäuser J; Rogers PD
Eukaryot Cell; 2012 Oct; 11(10):1289-99. PubMed ID: 22923048
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
45. Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis.
Zhang MR; Zhao F; Wang S; Lv S; Mou Y; Yao CL; Zhou Y; Li FQ
BMC Infect Dis; 2020 Feb; 20(1):126. PubMed ID: 32046674
[TBL] [Abstract][Full Text] [Related]
46. Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris.
Li J; Coste AT; Bachmann D; Sanglard D; Lamoth F
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0006722. PubMed ID: 35343781
[TBL] [Abstract][Full Text] [Related]
47. Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans.
Feng W; Yang J; Xi Z; Qiao Z; Lv Y; Wang Y; Ma Y; Wang Y; Cen W
Microb Drug Resist; 2017 Jul; 23(5):563-570. PubMed ID: 27976986
[TBL] [Abstract][Full Text] [Related]
48. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.
Sanglard D; Ischer F; Koymans L; Bille J
Antimicrob Agents Chemother; 1998 Feb; 42(2):241-53. PubMed ID: 9527767
[TBL] [Abstract][Full Text] [Related]
49. MDR1 overexpression combined with ERG11 mutations induce high-level fluconazole resistance in Candida tropicalis clinical isolates.
Jin L; Cao Z; Wang Q; Wang Y; Wang X; Chen H; Wang H
BMC Infect Dis; 2018 Apr; 18(1):162. PubMed ID: 29631565
[TBL] [Abstract][Full Text] [Related]
50. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.
Holmes AR; Keniya MV; Ivnitski-Steele I; Monk BC; Lamping E; Sklar LA; Cannon RD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1508-15. PubMed ID: 22203607
[TBL] [Abstract][Full Text] [Related]
51. Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and
Nishimoto AT; Zhang Q; Hazlett B; Morschhäuser J; Rogers PD
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833425
[TBL] [Abstract][Full Text] [Related]
52. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents.
Sanglard D; Ischer F; Parkinson T; Falconer D; Bille J
Antimicrob Agents Chemother; 2003 Aug; 47(8):2404-12. PubMed ID: 12878497
[TBL] [Abstract][Full Text] [Related]
53. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.
Chowdhary A; Prakash A; Sharma C; Kordalewska M; Kumar A; Sarma S; Tarai B; Singh A; Upadhyaya G; Upadhyay S; Yadav P; Singh PK; Khillan V; Sachdeva N; Perlin DS; Meis JF
J Antimicrob Chemother; 2018 Apr; 73(4):891-899. PubMed ID: 29325167
[TBL] [Abstract][Full Text] [Related]
54. Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans.
Pourakbari B; Teymuri M; Mahmoudi S; Valian SK; Movahedi Z; Eshaghi H; Mamishi S
Infect Disord Drug Targets; 2017; 17(3):178-184. PubMed ID: 28558643
[TBL] [Abstract][Full Text] [Related]
55. Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia.
Rosana Y; Yasmon A; Lestari DC
J Med Microbiol; 2015 Sep; 64(9):1046-1052. PubMed ID: 26297039
[TBL] [Abstract][Full Text] [Related]
56. Pan-azole-resistant Meyerozyma guilliermondii clonal isolates harbouring a double F126L and L505F mutation in Erg11.
Moreau J; Noël T; Point K; Tewes F; Deroche L; Clarhaut J; Fitton-Ouhabi V; Perraud E; Marchand S; Buyck JM; Brunet K
Mycoses; 2024 Mar; 67(3):e13704. PubMed ID: 38429226
[TBL] [Abstract][Full Text] [Related]
57. Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitals.
Manastır L; Ergon MC; Yücesoy M
Mycoses; 2011 Mar; 54(2):99-104. PubMed ID: 19732347
[TBL] [Abstract][Full Text] [Related]
58. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans.
Xiang MJ; Liu JY; Ni PH; Wang S; Shi C; Wei B; Ni YX; Ge HL
FEMS Yeast Res; 2013 Jun; 13(4):386-93. PubMed ID: 23480635
[TBL] [Abstract][Full Text] [Related]
59. Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs.
Mount HO; Revie NM; Todd RT; Anstett K; Collins C; Costanzo M; Boone C; Robbins N; Selmecki A; Cowen LE
PLoS Genet; 2018 Apr; 14(4):e1007319. PubMed ID: 29702647
[TBL] [Abstract][Full Text] [Related]
60. [Investigation of the expression levels of efflux pumps in fluconazole-resistant Candida albicans isolates].
Gulat S; Doluca Dereli M
Mikrobiyol Bul; 2014 Apr; 48(2):325-34. PubMed ID: 24819270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
